Paclitaxel (Paclitaxel) (Injection) 6 mg/mL

Paclitaxel is an antineoplastic agent used in the treatment of various types of cancer. It is effective in the following conditions:

• Breast cancer: Used as adjuvant therapy or in combination with other drugs to treat metastatic breast cancer.
• Ovarian cancer: Used in combination with cisplatin or carboplatin for primary treatment, or as a single agent for secondary treatment.
• Non-small cell lung cancer: Used in combination with cisplatin for the first-line treatment of advanced non-small cell lung cancer.
• Kaposi sarcoma: Used in the treatment of AIDS-related Kaposi's sarcoma.
• Pancreatic cancer: Used in the treatment of advanced pancreatic cancer.

• Paclitaxel works by stabilizing microtubules and preventing their depolymerization, which inhibits cell division. This action disrupts the normal function of the microtubule network, essential for vital interphase and mitotic cellular functions, leading to cell death.

Paclitaxel can cause various side effects, ranging from common to serious or rare.

Common Side Effects

• Nausea and vomiting
• Diarrhea
• Fatigue
• Hair loss (alopecia)
• Peripheral neuropathy
• Myalgia (muscle pain)
• Joint pain
• Anemia

Serious or Rare Side Effects

• Severe hypersensitivity reactions, including anaphylaxis
• Bone marrow suppression, leading to neutropenia and thrombocytopenia
• Severe peripheral neuropathy
• Cardiovascular events, such as hypotension and bradycardia
• Infections due to immunosuppression
• Hepatotoxicity
• Radiation recall reactions

Paclitaxel should be used with caution and under the supervision of a healthcare professional. Important precautions include:

• Monitor for bone marrow suppression: Frequent peripheral blood cell counts should be obtained.
• Premedication: Patients should be premedicated with corticosteroids, diphenhydramine, and histamine H2-receptor antagonists to reduce the risk of hypersensitivity reactions.
• Hepatic impairment: Caution should be exercised in patients with moderate hepatic impairment.
• Cardiac function: Monitor cardiac function if conduction abnormalities result.
• Pregnancy: Paclitaxel is contraindicated in pregnancy due to potential harm to the fetus.
• Breastfeeding: Not recommended for breastfeeding patients.
• Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Paclitaxel can interact with various drugs, which may affect its efficacy or increase the risk of side effects.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., carbamazepine, phenobarbital, rifampicin): May reduce the levels or effects of paclitaxel.
• CYP3A4 inhibitors (e.g., azole antifungals, clarithromycin, protease inhibitors): May increase the levels or effects of paclitaxel.
• Anthracyclines (e.g., doxorubicin, epirubicin): May increase levels or toxicity; administer anthracycline at least 24 hours prior to paclitaxel.
• Grapefruit products: Inhibits CYP3A4 metabolism, which may increase the serum concentration of paclitaxel.
• Echinacea: May decrease the effectiveness of immunosuppressants and induce CYP3A4, increasing paclitaxel metabolism.

Moderate Interactions (Monitor Closely)

• CYP2C8 inducers (e.g., carbamazepine, phenobarbital, rifampicin): May reduce levels or effects of paclitaxel.
• CYP2C8 inhibitors (e.g., gemfibrozil, ketoconazole, montelukast): May increase levels or effects of paclitaxel.
• Cardiac glycosides (e.g., digoxin): Paclitaxel may decrease their absorption; levels should be monitored.